ArticleBMC nephrology2026
Clinical and genetic features in 30 children with Gitelman syndrome.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coexistence of 21-hydroxylase deficiency and Gitelman syndrome in a neonate presenting with severe hyponatremic seizures: a case report.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundGitelman syndrome (GS) is a rare autosomal recessive renal tubular disorder caused by SLC12A3 gene variants. This study aimed to retrospectively analyze the clinical and genetic characteristics of pediatric GS patients and validate the function of a novel splicing variant.
methodsThirty genetically confirmed GS patients admitted to the Children’s Hospital of Nanjing Medical University between August 2017 and October 2025 were enrolled. We systematically reviewed clinical data, biochemical profiles, and SLC12A3 variants. We performed Minigene splicing analysis to verify the functional impact of the novel intronic variant c.1925 + 5G > T (NM_000339.3).
resultsAll 30 patients presented with hypokalemia, and 90% (27/30) had hypomagnesemia. Fatigue (43.3%, 13/30) and short stature (36.7%, 11/30) were the most common clinical manifestations. A total of 37 SLC12A3 variants were identified, including 20 missense variants (54%), eight splicing variants (21.6%), six frameshift variants (16.2%), one synonymous variant, one deletion, and one duplication. We discovered four novel variants: c.2531T > G (NM_000339.3) (p.(Leu844Arg)), c.1925 + 5G > T(NM_000339.3), c.2960_2962dup(NM_000339.3) (p.(Ser987_Ser988insCys)), and p.(Phe535Cysfs*108). Minigene splicing assay confirmed that c.1925 + 5G > T induced complete skipping of exon 15, leading to in vitro validated truncated mRNA due to abnormal splicing of the SLC12A3 transcript.
conclusionsPediatric GS presents with an insidious onset, and fatigue and short stature are the most common clinical manifestations in this single-center cohort. SLC12A3 variants are highly heterogeneous, with p.(Asp486Asn) and p.(Thr60Met) being frequent hotspots in the Chinese pediatric population. The novel splicing variant c.1925 + 5G > T contributes to GS pathogenesis by disrupting mRNA splicing. This study expands the SLC12A3 variant spectrum and provides clinical and experimental evidence for the early diagnosis and genetic counseling of pediatric GS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.